胆酸腹的新发展
Michael Camilleri1, Joelle BouSaba1
1Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Gastroenterology & hepatology
|September 29, 2023
概括
胆酸性腹 (BAD) 导致频繁,紧急的肠道排便,并且经常被误诊. 新的诊断测试和治疗方法,如利拉格卢提德,为这种影响生活质量的疾病提供了更好的管理.
科学领域:
- 胃肠病学 胃肠病学
- 消化系统疾病 消化系统疾病
- 临床医学 临床医学
背景情况:
- 胆酸性腹 (BAD) 呈现出严重的腹,紧迫性和生活质量的降低,经常被误认为是IBS-D或功能性腹.
- 病理生理学涉及加速的结肠过渡,增加的粘膜透性和改变的肠道微生物群与损害的胆酸代谢.
- 目前的诊断局限性存在,黄金标准 (48小时便胆酸分泌) 是繁的,而已建立的测试在美国无法使用.
研究的目的:
- 为提供关于胆酸腹 (BAD) 的最新概述.
- 涵盖BAD的病理生理学,诊断挑战和不断变化的治疗格局.
- 突出BAD诊断和治疗策略的最新进展.
主要方法:
- 关于胆酸腹 (BAD) 病理生理学,诊断和治疗的当前文献的综述.
- 对现有和新型BAD疗法的最新临床试验数据的分析.
- 讨论新兴的诊断工具及其临床影响.
主要成果:
- 最近对初级胆汁酸测量和禁食血清标记物的联合验证,为BAD提供了实用的临床诊断测试.
- 临床试验证明了colesevelam和liraglutide的疗效,在一项研究中,liraglutide显示出对colesevelam的优越性.
- 新的治疗点,包括Farnesoid X受体激动剂和纤维细胞生长因子19类似物,正在研究中.
结论:
- 胆酸腹 (BAD) 是一个独特的实体,经常被误诊,需要改进诊断方法.
- 有效的药理疗法可用,对新药和机制的研究正在进行中.
- 诊断和治疗方面的进步有望为BAD患者提供更好的管理和改善生活质量.
相关概念视频
Chronic Bowel Disorders: Introduction
474
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
474
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
348
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
348
Drugs for Treatment of Diarrhea-Predominant IBS
200
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
200
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
237
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
237
Drugs for Treatment of Constipation-Predominant IBS
197
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
197
Inflammatory Bowel Disease I: Ulcerative Colitis
207
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
207


